Be TRI

ABSTRACT: Interventions: Patients receive 12 cycle of FOLFOXIRI+Bmab therapy (Bmab:5mg/kg, CPT-11:165mg / m 2, L-OHP:85mg/m, l-LV:200mg/m2, Infusional 5-FU:3200mg / m2) every 2 weeks.(Or continue until conflicting with cancellation criteria) Primary outcome(s): Response rate Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Patients With Untreated Metastatic Colorectal Cancer

PROVIDER: 2615585 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR